Non-Invasive Prenatal Testing Market Size to Hit USD 8.14 BN by 2030

According to Nova one advisor, the global Non-invasive Prenatal Testing market size was valued at USD 2.9 billion in 2021 and is predicted to hit USD 8.14 billion by 2030 with a registered CAGR of 14.9% during the forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7317

Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma. NIPT screens for trisomy 21 (Down syndrome) as well as two other less common chromosome abnormalities: trisomy 13 and trisomy 18. Several companies are striving to create advanced screening methods that are sensitive and accurate in the early diagnosis of genetic abnormalities in infants. Next-generation sequencing (NGS) is a commonly used technology for the identification of trisomy, micro-deletions, and aneuploidies in chromosomes. NGS-based noninvasive prenatal tests are different from other techniques, as they can be performed as early as 10 weeks of pregnancy. Additionally, other noninvasive prenatal tests offer about 96% accuracy, while NGS-based tests are more than 99% accurate.

Report Scope of the Non-invasive Prenatal Testing Market

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7317

Better Accuracy and Short Duration of Procedure Augmenting Global Non-invasive Prenatal Testing Market Size

High incidence rate of babies born with Down’s syndrome and Turners’ syndrome across the globe is likely to drive the demand for non-invasive prenatal testing, primarily due to the high level of accuracy and safety offered over conventional screening and invasive diagnostic methods. Advantages of non-invasive prenatal tests, such as non-invasive nature, better accuracy, and short duration of the procedure, are anticipated to propel the global NIPT market during the forecast period.

According to sources from Down’s Syndrome Education (DSE) International, the prevalence of Down’s syndrome ranges from 1 in 1,500 to 1 in 400 babies born across different countries. Nearly 220,000 babies are born with Down’s syndrome globally every year. According to the CDC, the incidence rate stands at 1 in every 700 child births (around 6,000 annually) in the U.S. According to the Centers for Disease Control and Prevention (CDC), every year, around 6,000 babies born in the U.S suffer from Down’s syndrome, which is 1 in every 700 babies.

Increase in Maternal Age to Propel Global Non-invasive Prenatal Testing Market

Globally, the average age of first-time mothers is increasing, especially in developed countries such as the U.S., the U.K., France, Germany, Italy, and Japan. Financial stability, rising literacy rates, and social factors are responsible for the advancing maternal age. The risk of fetal chromosomal abnormalities is directly related to the rise in maternal age. According to the American Academy of Family Physicians (AAFP), the risk of fetal chromosomal abnormalities increases progressively up to the age of 30, then rapidly beyond that. According to sources, the chance of Down's syndrome in a newborn is 1/1,300 up to 25 years of maternal age, while the risk increases to 1/365 in pregnant women at 35 years of age and to 1/30 after 40 years. Thus, growth in average maternal age is likely to result in an increase in incidence of chromosomal abnormalities, leading to a rise in demand for NIPTs.

Strong Brand Reputation Fueling MaterniT21 Segment

In terms of test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others. The MaterniT21 segment accounted for significant share of the global non-invasive prenatal testing market in 2021. It is likely to be a highly lucrative segment during the forecast period. The MaterniT21 segment is anticipated to be driven by strong brand reputation of Labcorp and the expected collaboration with local distributors in the near future. In September 2019, Labcorp announced the findings of the largest research on cell-free DNA (cfDNA) screenings in multifetal pregnancies to date. The study, published in PLOS ONE (peer-reviewed open access scientific journal), concluded that non-invasive cfDNA screening with Labcorp's Integrated Genetics' MaterniT21 PLUS test delivered trustworthy findings that compared favorably to singleton pregnancies.

High Efficiency of NIPT in Screening of Down’s Syndrome Fueling Trisomy Segment

Based on application, the trisomy segment held significant share of the global NIPT market in 2021. It is likely to be a highly lucrative segment during the forecast period. According to the United Nations, the estimated rate of incidence of Down’s syndrome ranges from 1 in 1,000 live births per year to 1 in 1,100 live births per year globally. Around 95% cases of Down’s syndrome are nondisjunction cases, while translocation and mosaicism cases account for 5%. Dominance of the trisomy segment can be ascribed to then rise in prevalence of Down’s syndrome globally and high efficiency of NIPT for screening of Down’s syndrome. Similarly, maternal age is the most important risk factor for trisomy. Women in their late 30s and 40s have a higher chance of having trisomy. Thus, rise in average maternal age is anticipated to result in an increase in trisomy cases, which is likely to augment the segment.

Significant Popularity in NIPT Driving Next-generation Sequencing (NGS) Segment

In terms of technology, the next-generation sequencing (NGS) segment accounted for the largest global non-invasive prenatal testing market share in 2021. NGS has gained significant popularity in NIPT. Furthermore, majority of commercialized NIPT tests are based on the next-generation sequencing technology. For instance, MaterniT21 and Harmony are based on the NGS technique.

Improving Diagnostic Laboratory Infrastructure Bolstering Diagnostic Laboratories Segment

Based on end-user, the diagnostic laboratories segment is anticipated to grow at a rapid pace during the forecast period due to improving diagnostic laboratory infrastructure as compared to hospitals. Large number of diagnostic laboratories across the globe offer NIPT. MedGenome Labs Ltd. offers MedGenome Claria NIPT test for the diagnosis of Trisomies 21, 18, and 13; Monosomy X; and other sex chromosomal abnormalities. The company also offers Claria NIPT Plus, which is used to detect Down Syndrome, Edwards’ Syndrome, Patau Syndrome, Triploidy, Monosomy X (Turner Syndrome), Klinefelter Syndrome, Triple X, Jacob’s Syndrome, 22q11.2 Deletion Syndrome, 1p36 Deletion Syndrome, Prader-Willi Syndrome, Angelman Syndrome, and Cri-du-chat Syndrome.

Regional Outlook of Global Non-invasive Prenatal Testing Market

North America dominated the global market, with more than 61% share in 2021, followed by Europe. High rate of diagnosis and treatment of trisomy disorders, well-established healthcare infrastructure, and presence of key companies in the U.S. are likely to drive the non-invasive prenatal testing market in North America during the forecast period.

The market in Asia Pacific is projected to grow at the fastest CAGR during the forecast period owing to the rise in maternal age, which contributes to the increase in incidence of chromosomal aneuploidies in babies. Significant market developments in China and Japan, technological integration of NGS procedures, and improving healthcare infrastructure are the other factors propelling the market in the region.

Some of the prominent players in the Non-invasive Prenatal Testing Market include:

• Berry Genetics
• BGI
• Laboratory Corporation of America Holdings
• Agilent Technologies, Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Natera, Inc.
• PerkinElmer Inc.
• Eurofins LifeCodexx AG
• IGENOMIX
• Pacific Biosciences

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Non-invasive Prenatal Testing market

• Test Type
  • Materni21
  • Harmony
  • Panorama
  • Verifi
  • NIFTY
  • Others
• Application
  • Trisomy
  • Micro-deletions Symptoms
  • Others (including sex chromosomes disorders)
• Technology
  • NGS
  • WGS
  • Others
• End-user
  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7317

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/